Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
Assets | |||||
Current Assets | |||||
Cash & Cash Equivalents | 6,085,000 | 5,412,000 | 5,338,000 | 5,997,000 | 11,631,000 |
Marketable Securities | 1,179,000 | 973,000 | 1,182,000 | 1,411,000 | 12,721,000 |
Receivables | 4,660,000 | 4,777,000 | 4,493,000 | 4,892,000 | 3,582,000 |
Inventories | 1,787,000 | 1,507,000 | 1,618,000 | 1,683,000 | 922,000 |
TOTAL | $16,085,000 | $14,443,000 | $14,772,000 | $15,996,000 | $30,296,000 |
Non-Current Assets | |||||
PPE Net | 5,317,000 | 5,475,000 | 5,121,000 | 4,967,000 | 4,502,000 |
Investments And Advances | 1,163,000 | 1,245,000 | 1,309,000 | 502,000 | 1,488,000 |
Intangibles | 34,768,000 | 37,208,000 | 41,787,000 | 41,234,000 | 17,903,000 |
Other Non-Current Assets | 4,792,000 | 4,800,000 | 4,963,000 | 5,708,000 | 7,438,000 |
TOTAL | $46,040,000 | $48,728,000 | $53,180,000 | $52,411,000 | $31,331,000 |
Total Assets | $62,125,000 | $63,171,000 | $67,952,000 | $68,407,000 | $61,627,000 |
Liabilities | |||||
Current Liabilities | |||||
Short Term Debt | 1,798,000 | 2,273,000 | 1,516,000 | 2,757,000 | 2,499,000 |
Accounts payable and accrued liabilities | 550,000 | 905,000 | 705,000 | 844,000 | 713,000 |
Accrued Expenses | 3,802,000 | 3,479,000 | 3,244,000 | 3,460,000 | 3,473,000 |
Other current liabilities | 5,130,000 | 4,580,000 | N/A | N/A | N/A |
TOTAL | $11,280,000 | $11,237,000 | $11,610,000 | $11,397,000 | $9,759,000 |
Non-Current Liabilities | |||||
Long Term Debt | 24,469,000 | 24,136,000 | 26,155,000 | 29,859,000 | 23,103,000 |
aiOther Non-Current Liabilities | 2,091,000 | 3,942,000 | 4,791,000 | 5,050,000 | 6,137,000 |
TOTAL | $28,096,000 | $30,725,000 | $35,278,000 | $38,789,000 | $29,218,000 |
Total Liabilities | $39,376,000 | $41,962,000 | $46,888,000 | $50,186,000 | $38,977,000 |
Shareholders' Equity | |||||
Shares Outstanding, K | 1,245,775 | 1,247,105 | 1,253,887 | 1,256,593 | 1,263,637 |
Common Shares | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 |
Retained earnings | 16,304,000 | 15,687,000 | 16,324,000 | 14,381,000 | 19,388,000 |
Other shareholders' equity | -56,000 | -29,000 | 78,000 | -41,000 | 210,000 |
TOTAL | $22,749,000 | $21,209,000 | $21,064,000 | $18,221,000 | $22,650,000 |
Total Liabilities And Equity | $62,125,000 | $63,171,000 | $67,952,000 | $68,407,000 | $61,627,000 |